Prospective evaluation of the proportion of sessile serrated adenoma/polyps in endoscopically diagnosed colorectal polyps with hyperplastic features

Authors
Wataru Sano, Yasushi Sano, Mineo Iwatate, Noriaki Hasukui, Santa Hattori, Hidekazu Kosaka, Taro Ikumoto, Masahito Kotaka, Takahiro Fujimori

Institutions
1 Gastrointestinal Center, Sano Hospital, Hyogo, Japan
2 Department of Pathology, Shinko Hospital, Hyogo, Japan

Background and study aims: Sessile serrated adenoma/polyps (SSA/Ps) are considered precursors of colorectal cancers with microsatellite instability. However, it is still difficult to differentiate SSA/Ps from hyperplastic polyps endoscopically; therefore, the prevalence of SSA/Ps remains uncertain in clinical practice. This study aimed to clarify the proportion of SSA/Ps in endoscopically diagnosed colorectal polyps with hyperplastic features (E-HPs).

Patients and methods: Patients aged ≥40 years undergoing colonoscopy for standard clinical indications at our center were prospectively enrolled between June 2013 and May 2014. During colonoscopy, 0.05% indigo carmine dye was sprayed throughout the colorectum to highlight lesions. All detected lesions were diagnosed by high definition magnifying narrow-band imaging and were resected endoscopically or surgically, apart from rectosigmoid E-HPs ≤5 mm. The number of SSA/Ps from hyperplastic polyps endoscopically; therefore, the prevalence of SSA/Ps remains uncertain in clinical practice. This study aimed to clarify the proportion of SSA/Ps in endoscopically diagnosed colorectal polyps with hyperplastic features (E-HPs).

Results: A total of 343 patients (male: 42.9%; mean age: 61.5 years) were included. Among 3838 E-HPs (distal: 96.4%) detected in 294 patients, 792 were resected and analyzed. All of 21 SSA/Ps identified in 17 patients were included in E-HPs, and the overall proportion of SSA/Ps in E-HPs was 2.7%. However, this proportion increased with the size of E-HPs (≤5 mm: 0.7%; 6–9 mm: 29.0%; ≥10 mm: 70%) and was higher in the proximal colon than in the distal colorectum (10.9% vs. 0.9%). In addition, no SSA/P was found in the rectum, and no SSA/P had cytological dysplasia.

Conclusions: The overall proportion of SSA/Ps in E-HPs was 2.7%, although this proportion was higher in the proximal colon and increased with the size of E-HPs. SSA/Ps were common in routine colonoscopy, with a prevalence of at least 5.0%. Study registration: UMIN000010832.

Introduction

In recent years, the serrated neoplastic pathway arising from serrated lesions has attracted much attention as a new colorectal carcinogenic pathway by which approximately 20% of all colorectal cancers are believed to develop. At present, colorectal serrated lesions are classified as hyperplastic polyps (HPs), sessile serrated adenoma/polyps (SSA/Ps) with or without cytological dysplasia, or traditional serrated adenomas (TSAs) according to the World Health Organization criteria. Of these serrated lesions, SSA/Ps and TSAs are considered premalignant, and SSA/Ps are believed to be the most potent precursors of colorectal cancers with microsatellite instability because of their genetic backgrounds including BRAF gene mutations and hypermethylation of CpG islands in the promoter regions of tumor suppressor genes (i.e. the CpG island methylator phenotype). Recent image enhancement techniques have improved the diagnostic accuracy of differential diagnosis between neoplastic and non-neoplastic colorectal lesions by >90% in real-time histology [1,2]. Of the serrated lesions, TSAs are commonly reddish, pinecone- or branch coral-shaped, protruded lesions with a type IIIH (fern-like) or IVH (pinecone-like) pit pattern [3]; thus, it is not difficult to distinguish them from other serrated lesions and diagnose them as neoplasia. Conversely, most SSA/Ps are normal in color or discolored flat lesions similar to HPs; thus, SSA/Ps may often be misdiagnosed as HPs. Although the endoscopic features of SSA/Ps, such as a type II-O pit pattern and a mucous cap, have been reported over recent years [4,5], it remains difficult to differentiate SSA/Ps from HPs even by image-enhanced endoscopy.
Therefore, we designed this study to clarify the proportion of SSA/Ps in endoscopically diagnosed colorectal polyps with hyperplastic features (E-HPs). We believe that elucidation of the proportion of SSA/Ps in E-HPs will enhance current knowledge with regard to SSA/Ps and advance the treatment of E-HPs.

**Patients and methods**

**Patients and exclusion criteria**

A total of 364 patients aged ≥40 years undergoing colonoscopy for standard clinical indications at our center were prospectively enrolled in this study between June 2013 and May 2014 (Fig.1). Patients with a history of polypectomy for colorectal serrated lesions or surgical colorectal resection, patients with inflammatory bowel disease or colorectal polyposis, and patients with poor bowel preparation or incomplete colonoscopy were excluded. In addition, informed consent was obtained from all patients, apart from six patients; thus, they were also excluded. The study protocol was approved by the local institutional review board (SH09-13). The clinical trial was registered in the University Hospital Medical Information Network Center (UMIN000010832).

**Colonoscopy**

All patients received 1.8 L of isotonic magnesium citrate solution for bowel preparation. Colonoscopies were performed by six experienced gastrointestinal endoscopists using a high definition magnifying video colonoscope equipped with a waterjet function (CF-HQ290I, PCF-Q260AZI, EVIS 290 system; Olympus Medical Systems, Tokyo, Japan). During colonoscopy, 0.05% indigo carmine solution was sprayed throughout the colorectum to highlight lesions using the waterjet function. All detected lesions were diagnosed by magnifying narrow-band imaging (NBI), according to the NBI international colorectal endoscopic classification [6,7], and were resected endoscopically or surgically, apart from rectosigmoid E-HPs ≤5 mm. The number of rectosigmoid E-HPs ≤5 mm was recorded by a tally counter, and some were resected endoscopically for use as tissue samples to confirm the quality assurance of real-time histology by magnifying colonoscopy. Polyps ≤2 mm were removed using cold biopsy forceps in a single bite, and those ≥3 mm were resected by a hot snare procedure. All lesions were measured by comparison with open or closed biopsy forceps or polypectomy snare. Cecal intubation was confirmed by identification of the appendiceal orifice. Withdrawal time was recorded using a stopwatch after subtracting the time needed for biopsy or polypectomy. The proximal colon was defined as proximal to the splenic flexure, i.e. cecum, ascending colon, and transverse colon.

**Histopathology**

Resected specimens were evaluated by an experienced gastrointestinal pathologist (T.F.) who was a member of the Japanese Society for Cancer of the Colon and Rectum (JSCCR) and was well versed in the diagnosis of colorectal serrated lesions. Histopathological diagnosis was based on the morphological features on hematoxylin and eosin staining. Of the serrated lesions, HPs were defined by a serrated epithelial architecture in the upper part of the crypts, proliferative zones limited to the lower part of the crypts, and the absence of cytological dysplasia. SSA/Ps were distinguished from HPs by the following JSCCR criteria: (1) crypt dilation, (2) irregularly branching crypts, and (3) horizontally arched basal crypts (inverted T- and/or L-shaped crypts) [8,9]. When at least two of these three findings were seen in the areas of ≥10% of the lesions, the serrated lesions were diagnosed as SSA/Ps. However, the serrated lesions which did not meet the above criteria were diagnosed as HPs. TSAs were defined by villiform growth, serrated epithelium in association with nuclear and cytologic atypia, ectopic crypt formation, and eosinophilic cytoplasm.

After the study, all resected specimens of SSA/Ps and TSAs intermingled with some resected specimens of HPs and conventional adenomas were reevaluated by the same pathologist to confirm the final pathological diagnoses. At this time, the pathologist was blinded to the clinical data, such as the endoscopic diagnosis, the initial pathological diagnosis, and the anatomical location, size, and shape of the lesions.

**Statistical analysis**

Differences in the proportion of SSA/Ps in E-HPs were assessed using the chi-squared test or Fisher’s exact test, as appropriate. Two-sided P values of <0.05 were considered statistically significant.

**Results**

**Patients and colonoscopy**

A total of 343 eligible patients (male: 42.9%) with a mean age of 61.5 years (range: 40–86 years) were included in this study (Fig.1). The indications for colonoscopy were positive fecal occult blood test (n=1138), any abdominal symptom (n=86), post-polypectomy surveillance (n=60), and screening (n=59). The mean and median withdrawal times during colonoscopy were 9.5 min and 8.9 min, respectively. The adenoma detection rate was 56.0%.

**Histopathology**

A total of 1301 lesions were resected endoscopically or surgically and then analyzed histopathologically. Among them, 21 were SSA/Ps, 13 were TSAs, 472 were conventional adenomas, 29 were adenocarcinomas (intramusosal: 16; invasive: 13), 1 was a neuroendocrine tumor (grade 1), and 2 were juvenile polyps. The remaining 763 lesions were HPs, hyperplastic nodules, or colorectal mucosa.
Prevalence of E-HPs
A total of 3838 lesions were endoscopically diagnosed as HPs (Table 1). The overall prevalence of E-HPs, defined as the proportion of patients with ≥1 E-HP, was 85.7% of 343 patients. The prevalence of E-HPs ≤5 mm, 6–9 mm, and ≥10 mm was 85.7%, 6.1%, and 2.6%, respectively. The prevalence of proximal and distal E-HPs was 23.9% and 85.1%, respectively. In addition, 13.6% and 13.0% of conventional adenomas ≤5 mm were misdiagnosed as HPs in the proximal and distal colorectum, respectively.

Prevalence of SSA/Ps
A total of 21 SSA/Ps were identified in 17 of 343 patients, and the prevalence of SSA/Ps, defined as the proportion of patients with ≥1 SSA/P, was 5.0%. However, there was no SSA/P with cytological dysplasia in 343 patients (95% confidence interval (CI): 0–0.9). Fig. 2 shows an example of an SSA/P identified and resected endoscopically in this study.

Proportion of SSA/Ps in E-HPs
Among 3838 E-HPs (distal: 96.4%), 792 were endoscopically resected and histopathologically analyzed. All of 21 SSA/Ps were included in E-HPs, and the overall proportion of SSA/Ps in 792 E-HPs was 2.7% (Table 2). However, this proportion significantly increased with the size of E-HPs (≤5 mm: 0.7%; 6–9 mm: 29.0%; ≥10 mm: 70%) and was significantly higher in the proximal colon than in the distal colorectum (10.9% vs. 0.9%). In addition, no SSA/P was found in the rectum.

Diagnostic accuracy
The diagnostic accuracy of differential diagnosis between neoplasia and non-neoplasia for all resected lesions was 92.2% [sensitivity: 89.1%; specificity: 94.3%; positive predictive value (PPV): 91.1%; negative predictive value (NPV): 93.0%], and that for rectosigmoid lesions resected endoscopically was 95.5% (sensitivity: 85.4%; specificity: 97.4%; PPV: 86.8%; NPV: 97.1%).

Discussion
To the best of our knowledge, this is the first prospective study to examine the proportion of SSA/Ps in E-HPs and the prevalence of SSA/Ps in Japanese patients undergoing routine colonoscopy, using pan-colonic chromoendoscopy with high definition magnifying NBI colonoscopy.

Previous studies have demonstrated that pan-colonic chromoendoscopy with indigo carmine dye improves the detection of colorectal polyps, including serrated lesions, compared with conventional colonoscopy [10–12]. Furthermore, the diagnostic accuracy of magnifying NBI colonoscopy in differential diagnosis between neoplastic and non-neoplastic colorectal lesions is similar to that of magnifying chromoendoscopy but greater than that of conventional colonoscopy [2]. Therefore, in this study, we used pan-colonic chromoendoscopy to detect lesions and magnifying NBI colonoscopy, which is simpler and more convenient than...
chromoendoscopy, to arrive at a diagnosis, and then analyzed the resected lesions histopathologically. In previous studies, indigo carmine solution has been used at concentrations ranging from 0.05% to 0.4% for pan-colonic chromoendoscopy [10–13]. Although we routinely use 0.2% indigo carmine solution to observe colorectal lesions during chromoendoscopy at our center, we found that 0.2% indigo carmine solution affected the NBI observation in a pretest before the study. Hence, in this study, we used 0.05% indigo carmine solution, which was sufficient to highlight lesions and did not affect the NBI observation in the pretest.

Yano et al. clarified the prevalence and distribution of various-sized E-HPs by pan-colonic chromoendoscopy with 0.05% indigo carmine dye [13]. In their prospective study, 3060 E-HPs were detected in 226 of 263 patients, and the prevalence of E-HPs was 85.9%. Moreover, E-HPs 6–9 mm and those ≥10 mm were predominantly located in the proximal colon compared with E-HPs ≤5 mm. These findings are consistent with the results of the present study (Table 1). However, in their study, E-HPs were not evaluated histopathologically; hence, the proportion of SSA/Ps in E-HPs remained unknown.

In the present study, the overall proportion of SSA/Ps in 792 E-HPs was 27.7% (Table 2). However, this proportion significantly increased with the size of E-HPs and was significantly higher in the proximal colon than in the distal colorectum. Moreover, no SSA/P was found in the rectum. These findings confirm the knowledge gained in previous studies that the size is a predictor of SSA/P histology and SSA/Ps are predominantly found in the proximal colon [14–17]. If possible, complete resection of all E-HPs may be preferable for the prevention of colorectal cancers. However, such an unremitting procedure is not acceptable because of the increased workload for endoscopists and pathologists, the increased medical costs, and the probable adverse events (e.g. bleeding and perforation). Therefore, we propose the resection of all E-HPs apart from distal E-HPs ≤5 mm, as an international expert panel recently recommended complete removal of all serrated lesions apart from diminutive sigmoid or rectal lesions [18]. Our proposal is based on the fact that, although a large number of distal E-HPs ≤5 mm were detected, the proportion of SSA/Ps in them was quite low (0.5%) (Table 2). If we applied this proposal to the present study, 155 E-HPs would have been resected in 25.4% of 343 patients, which is acceptable in routine clinical practice. However, in the present study, 3.0% of resected distal E-HPs ≤5 mm were conventional adenomas. Furthermore, 13.0% of distal conventional adenomas ≤5 mm were misdiagnosed as HPs, even by high definition magnifying colonoscopy, and these lesions have a risk of becoming interval cancers. Therefore, to avoid leaving neoplastic lesions in situ, we recommend resecting the distal E-HPs ≤5 mm for which the optical diagnoses are not highly confident.

In the present study, most of the rectosigmoid E-HPs ≤5 mm were not evaluated histopathologically, although SSA/Ps were common, with a prevalence of 5.0%. Moreover, the prevalence of SSA/Ps was also high (10.2%) in 59 asymptomatic patients who underwent screening colonoscopy among 343 patients. In previous studies, the prevalence of SSA/Ps has been reported to range from 0.5% to 13.8% [15–17, 19–23]. This variability is probably due to the differences in study design and population, colonoscopy equipment and observation method, experience of the endoscopists, and the histopathological diagnostic criteria of SSA/Ps. However, it is noteworthy that the prevalence of SSA/Ps was high (13.8%) in a previous prospective study using chromoendoscopy with indigo carmine dye [15]. Furthermore, Le Rhun et al. reported that pan-colonic chromoendoscopy improves the detection of HPs [12], and indeed, the prevalence of E-HPs was quite high (85.7%) in the present study. Therefore, the higher prevalence of SSA/Ps in studies, including our study, using chromoendoscopy than in previous studies using conventional colonoscopy with white light suggests that pan-colonic chromoendoscopy may also improve the detection of SSA/Ps, and SSA/Ps may often be overlooked during conventional colonoscopy. However, pan-colonic chromoendoscopy appears to be unacceptable for routine examinations because of increased costs and procedure time [10, 11]. In addition, the usefulness of NBI for the detection of colorectal polyps still remains controversial [24]. Therefore, at present, it is necessary to be careful not to overlook E-HPs, particularly in the proximal colon, during conventional colonoscopy.

Moreover, Butterly et al. reported recently that a median normal withdrawal time of 9 min resulted in a statistically significant increase in colorectal adenoma and serrated polyp detection [25]. This is consistent with the mean and median withdrawal times in the present study, which were 9.5 min and 8.9 min, respectively. Therefore, even though pan-colonic chromoendoscopy cannot be applied to routine examinations, colonoscopy with a median normal withdrawal time of 9 min may improve the detection rates of E-HPs including SSA/Ps.

In the present study, there was no SSA/P with cytological dysplasia in 343 patients (95.3%; 0–0.9). Although we cannot exclude the possibility that some SSA/Ps with cytological dysplasia were present in the non-resected distal E-HPs ≤5 mm, the prevalence of SSA/Ps with cytological dysplasia has been reported to be quite low (0.2–0.8% of patients) in previous studies as well [16, 19–21], which suggests that SSA/Ps with cytological dysplasia may be rare in clinical practice. However, many previous case reports of SSA/Ps with carcinoma, including those showing rapid pro-

### Table 1

<table>
<thead>
<tr>
<th>Size</th>
<th>Proximal colon</th>
<th>Distal colorectum</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤5 mm, % (95%CI)</td>
<td>1.8 (0.2–6.2)</td>
<td>0.5 (0.1–1.4)</td>
<td>0.7 (0.2–1.5)</td>
</tr>
<tr>
<td>6–9 mm, % (95%CI)</td>
<td>43.8 (19.8–70.1)</td>
<td>13.3 (1.7–40.5)</td>
<td>29.0 (14.2–48.0)</td>
</tr>
<tr>
<td>≥10 mm, % (95%CI)</td>
<td>85.7 (42.1–99.6)</td>
<td>33.3 (0.8–90.6)</td>
<td>70.1 (34.8–93.3)</td>
</tr>
<tr>
<td>Total, % (95%CI)</td>
<td>10.9 (6.3–17.4)</td>
<td>0.9 (0.3–2.0)</td>
<td>2.7 (1.7–4.0)</td>
</tr>
</tbody>
</table>

All 21 SSA/Ps identified in 17 patients were included in E-HPs, and the overall proportion of SSA/Ps in 792 E-HPs was 2.7%. There was no SSA/P with cytological dysplasia.

Table 2 Proportion of sessile serrated adenoma/polyps (SSA/Ps) in endoscopically diagnosed colorectal polyps with hyperplastic features (E-HPs).

1 P=0.01 vs. ≤5 mm
2 P=0.05 vs. 6–9 mm
3 P=0.01 vs. distal, chi-squared test or Fisher’s exact test.
gession, have demonstrated the malignant potential of SSA/Ps [26 – 29]. Importantly, most of these carcinomas developed in the proximal colon. In addition, it has been reported that interval cancers are more likely to develop in the proximal colon and exhibit microsatellite instability than non-interval cancers [30]. This growing evidence indicates that some SSA/Ps may be overlooked or incompletely resected during colonoscopy, rapidly progress to carcinoma, and lead to interval cancers. Therefore, it is becoming increasingly important to ensure that E-HPs, particularly in the proximal colon, are detected and completely resected during colonoscopy.

This study has a limitation that 3046 rectosigmoid E-HPs in 3683 during colonoscopy. larly in the proximal colon, are detected and completely resected

References

Competing interests: None

Table 2

<table>
<thead>
<tr>
<th>E358</th>
<th>Original article</th>
</tr>
</thead>
</table>

Sano Wataru et al. Sessile serrated adenoma/polyps in endoscopically diagnosed colorectal polyps ... Endosc Int Open 2015; 03: E354–E358